Cost-Effectiveness Analysis of an Implantable Device for Chronic Gastro-Oesophageal Reflux Disease in Sweden

Author(s)

Lundell L1, Kartha M2, Harper S3, Mealing S4
1Karolinska Institutet, Stockholm, Sweden, 2Implantica, Epsom, SRY, UK, 3York Health Economics Consortium, York, UK, 4York Health Economics Consortium, York, York, UK

OBJECTIVES: Gastro-oesophageal reflux disease (GORD) is common in the European population. In Sweden, proton pump inhibitors (PPIs) are the standard treatment, with Nissen fundoplication as the standard of care surgical option for selected cases. RefluxStop is a device emerging as an alternative surgical option. The objective of this analysis was to evaluate the cost-effectiveness of RefluxStop compared to Nissen fundoplication and PPIs.

METHODS: A Markov model was developed based on a recent publication for the UK NHS to assess cost-effectiveness of RefluxStop against other treatments. The healthcare payer's perspective was adopted with a lifetime horizon, one-month cycle length, and 3% annual discount rate utilised. Health states included initial PPI use, PPI relapse, follow-on surgery, reoperations, higher-dose PPI, Barrett's esophagus, esophageal cancer, and death. The model incorporated adverse events associated with PPIs and surgeries, while benefits were measured in quality-adjusted life-years (QALYs). Unit costs were derived from Swedish diagnostic-related group tariffs and from medical literature. Clinical efficacy data came from publications in the literature. Uncertainty was explored through deterministic and probabilistic sensitivity analyses.

RESULTS: The lifetime difference in costs for RefluxStop relative to PPIs and Nissen fundoplication were SEK 86,684 and SEK 42,523 per person, while the difference in QALYs per patient gained were 1.80 and 0.68, respectively. Thus, the base case incremental cost-effectiveness ratios (ICERs) for RefluxStop compared to PPIs and Nissen fundoplication were SEK 48,152 and SEK 62,966 per QALY gained, respectively. At a cost-effectiveness threshold of SEK 500,000 per QALY gained, RefluxStop has a high likelihood of being cost-effective, with probabilities of 100% and 96% against PPIs and Nissen fundoplication, respectively. Model results remained robust with sensitivity analysis. In a scenario analysis with a 10-year time horizon, RefluxStop remained cost-effective compared to other options.

CONCLUSIONS: RefluxStop demonstrates strong potential as a cost-effective treatment for GORD in Sweden.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EE480

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Gastrointestinal Disorders, Surgery

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×